What is CircNova?
Founded in 2023 and headquartered in Detroit, Michigan, CircNova is a private biotechnology company at the forefront of developing RNA-based therapies. The company harnesses its proprietary AI NovaEngine, a sophisticated platform designed for the generation, analysis, and identification of circular RNA. This innovative approach targets "undruggable" disease targets, positioning CircNova to offer groundbreaking solutions for critical unmet clinical needs within the healthcare sector. The company's focus on cutting-edge AI and RNA technology signifies a commitment to pioneering new frontiers in medicine.
How much funding has CircNova raised?
CircNova has raised a total of $3.3M across 1 funding round:
Angel/Seed
$3.3M
Angel/Seed (2025): $3.3M with participation from Invest Detroit Ventures, Spark Capital, and South Loop Ventures
Key Investors in CircNova
Invest Detroit Ventures
Invest Detroit Ventures specializes in providing resources and insights for entrepreneurs looking to form LLCs across various states, offering guidance on business formation and financial management.
Spark Capital
Spark Capital invests in products by creators they admire, supporting founders across all sectors and stages with offices in San Francisco, Boston, and New York City.
South Loop Ventures
South Loop Ventures is a Pre-Seed and Seed stage venture fund based in Houston, TX, investing up to $500K in innovative founding teams aiming to reshape future economies, with a focus on Energy, Healthtech, Spacetech, Sportstech, and Fintech.
What's next for CircNova?
With the recent influx of major strategic investment and substantial overall capital, CircNova is poised for significant expansion and advancement. The enterprise-level funding suggests a transition towards scaling operations, potentially including clinical trial progression, further platform development, and strategic partnerships. The company's focus on AI-driven RNA therapeutics indicates a forward-looking strategy aimed at capturing a substantial share of the rapidly evolving biotechnology market. Future developments will likely center on translating their innovative technology into tangible therapeutic outcomes for patients.
See full CircNova company page
